EUVIMEDEUVIMED entdecken
Open Access

OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals

Alyssa Ylescupidez iD, Cate Speake iD, Susan L Pietropaolo, Darrell M Wilson, Andrea K Steck, Jennifer L Sherr iD, Jason L Gaglia, Christine Bender, Sandra Lord iD, Carla J Greenbaum

The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 57-67

DOI: 10.1210/clinem/dgad472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.08.2023. Verfasst von Alyssa Ylescupidez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Breakthrough T1D, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The value of continuous glucose monitoring (CGM) for monitoring autoantibody (AAB)-positive individuals in clinical trials for progression of type 1 diabetes (T1D) is unknown.

Objective

Compare CGM with oral glucose tolerance test (OGTT)–based metrics in prediction of T1D.

Methods

At academic centers, OGTT and CGM data from multiple-AAB relatives were evaluated for associations with T1D diagnosis. Participants were multiple-AAB–positive individuals in a TrialNet Pathway to Prevention (TN01) CGM ancillary study (n = 93). The intervention was CGM for 1 week at baseline, 6 months, and 12 months. Receiver operating characteristic (ROC) curves of CGM and OGTT metrics for prediction of T1D were analyzed.

Results

Five of 7 OGTT metrics and 29/48 CGM metrics but not HbA1c differed between those who subsequently did or did not develop T1D. ROC area under the curve (AUC) of individual CGM values ranged from 50% to 69% and increased when adjusted for age and AABs. However, the highest-ranking metrics were derived from OGTT: 4/7 with AUC ∼80%. Compared with adjusted multivariable models using CGM data, OGTT-derived variables, Index60 and DPTRS (Diabetes Prevention Trial-Type 1 Risk Score), had higher discriminative ability (higher ROC AUC and positive predictive value with similar negative predictive value).

Conclusion

Every 6-month CGM measures in multiple-AAB–positive individuals are predictive of subsequent T1D, but less so than OGTT-derived variables. CGM may have feasibility advantages and be useful in some settings. However, our data suggest there is insufficient evidence to replace OGTT measures with CGM in the context of clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HumansGlucose Tolerance TestBlood GlucoseAutoantibodiesBlood Glucose Self-MonitoringContinuous Glucose Monitoring

Stichwörter der Autor:innen

CGMOGTTpredictiontype 1 diabetes

Substanzen

Blood GlucoseAutoantibodies

Autor:innen und Institutionen

  • Center for Interventional Immunology and Diabetes Program, Benaroya Research Institute, Seattle, WA 98101, USA.
  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
  • Division of Pediatric Endocrinology, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
  • Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
  • Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT 06511, USA.
  • Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.

ORCID-Profile: Alyssa Ylescupidez, Cate Speake, Jennifer L Sherr, Sandra Lord

Förderung

  • Breakthrough T1D
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Juvenile Diabetes Research Foundation
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Ylescupidez, A., Speake, C., Pietropaolo, S. L., Wilson, D. M., Steck, A. K., Sherr, J. L., Gaglia, J. L., Bender, C., Lord, S., & Greenbaum, C. J. (2023). OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal of Clinical Endocrinology & Metabolism, 109(1), 57-67. https://doi.org/10.1210/clinem/dgad472

Vancouver

Ylescupidez A, Speake C, Pietropaolo SL, Wilson DM, Steck AK, Sherr JL, et al. OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):57-67. doi:10.1210/clinem/dgad472

BibTeX
@article{Ylescupidez2023,
  author = {Ylescupidez, Alyssa and Speake, Cate and Pietropaolo, Susan L and Wilson, Darrell M and Steck, Andrea K and Sherr, Jennifer L and Gaglia, Jason L and Bender, Christine and Lord, Sandra and Greenbaum, Carla J},
  title = {OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {109},
  number = {1},
  pages = {57--67},
  doi = {10.1210/clinem/dgad472}
}
Kostenlos starten →